Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation.

IF 2.5 Q3 ONCOLOGY Journal of Cancer Prevention Pub Date : 2021-06-30 DOI:10.15430/JCP.2021.26.2.145
Nam Ho Jeoung, Ji Yun Jeong, Bong Seok Kang
{"title":"Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation.","authors":"Nam Ho Jeoung,&nbsp;Ji Yun Jeong,&nbsp;Bong Seok Kang","doi":"10.15430/JCP.2021.26.2.145","DOIUrl":null,"url":null,"abstract":"<p><p>Cryptotanshinone is known for its inhibitory activity against tumorigenesis in various human cancer cells. However, exact mechanisms underlying the anticancer effects of cryptotanshinone are not fully elucidated. Here, we propose a plausible molecular mechanism, wherein cryptotanshinone represses rapamycin-sensitive mTORC1/S6K1 mediated cancer cell growth and cell transformation. We investigated the various effects of cryptotanshinone on the mTORC1/S6K1 axis, which is associated with the regulation of cell growth in response to nutritional and growth factor signals. We found that cryptotanshinone specifically inhibited the mTORC1-mediated phosphorylation of S6K1, which consequently suppressed the clonogenicity of SK-Hep1 cells and the neoplastic transformation of JB6 Cl41 cells induced by insulin-like growth factor-1. Finally, we observed that cryptotanshinone prevented S6K1 from binding to the Raptor/mTOR complex, rather than regulating mTOR and its upstream pathway. Overall, our findings provide a novel mechanism underlying anti-cancer effects cryptotanshinone targeting mTORC1 signaling, contributing to the development of anticancer agents involving metabolic cancer treatment.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"26 2","pages":"145-152"},"PeriodicalIF":2.5000,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/cc/jcp-26-2-145.PMC8249204.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15430/JCP.2021.26.2.145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Cryptotanshinone is known for its inhibitory activity against tumorigenesis in various human cancer cells. However, exact mechanisms underlying the anticancer effects of cryptotanshinone are not fully elucidated. Here, we propose a plausible molecular mechanism, wherein cryptotanshinone represses rapamycin-sensitive mTORC1/S6K1 mediated cancer cell growth and cell transformation. We investigated the various effects of cryptotanshinone on the mTORC1/S6K1 axis, which is associated with the regulation of cell growth in response to nutritional and growth factor signals. We found that cryptotanshinone specifically inhibited the mTORC1-mediated phosphorylation of S6K1, which consequently suppressed the clonogenicity of SK-Hep1 cells and the neoplastic transformation of JB6 Cl41 cells induced by insulin-like growth factor-1. Finally, we observed that cryptotanshinone prevented S6K1 from binding to the Raptor/mTOR complex, rather than regulating mTOR and its upstream pathway. Overall, our findings provide a novel mechanism underlying anti-cancer effects cryptotanshinone targeting mTORC1 signaling, contributing to the development of anticancer agents involving metabolic cancer treatment.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
隐丹参酮阻止S6K1与mTOR/Raptor结合,抑制mTORC1-S6K1信号活性和肿瘤细胞转化
隐丹参酮具有抑制多种人类癌细胞发生的活性。然而,隐丹参酮抗癌作用的确切机制尚未完全阐明。在这里,我们提出了一个合理的分子机制,其中隐丹参酮抑制雷帕霉素敏感的mTORC1/S6K1介导的癌细胞生长和细胞转化。我们研究了隐丹参酮对mTORC1/S6K1轴的各种影响,这与营养和生长因子信号对细胞生长的调节有关。我们发现隐丹参酮特异性抑制mtorc1介导的S6K1磷酸化,从而抑制SK-Hep1细胞的克隆性和胰岛素样生长因子-1诱导的JB6 Cl41细胞的肿瘤转化。最后,我们观察到隐丹参酮阻止S6K1与Raptor/mTOR复合物结合,而不是调节mTOR及其上游途径。总之,我们的研究结果为隐丹参酮靶向mTORC1信号的抗癌作用提供了一种新的机制,有助于开发涉及代谢性癌症治疗的抗癌药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
4.00%
发文量
32
期刊最新文献
Anticancer Activity of Phytochemicals of the Papaya Plant Assessed: A Narrative Review. Kaempferol Synergistically Enhances Cisplatin-induced Apoptosis and Cell Cycle Arrest in Colon Cancer Cells. Recommendations for Healthy Lifestyle for Cancer Prevention and Healthy Aging. Elevated N1-Acetylspermidine Levels in Doxorubicin-treated MCF-7 Cancer Cells: Histone Deacetylase 10 Inhibition with an N1-Acetylspermidine Mimetic. Ribosomal Protein L9 Maintains Stemness of Colorectal Cancer via an ID-1 Dependent Mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1